Delta Capital Management LLC bought a new stake in shares of Colgate-Palmolive (NYSE:CL – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,000 shares of the company’s stock, valued at approximately $208,000.
Other large investors also recently added to or reduced their stakes in the company. E Fund Management Hong Kong Co. Ltd. acquired a new position in Colgate-Palmolive during the 2nd quarter valued at about $25,000. Continuum Advisory LLC raised its position in shares of Colgate-Palmolive by 46.5% in the 2nd quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after acquiring an additional 125 shares during the period. Rise Advisors LLC acquired a new stake in shares of Colgate-Palmolive in the 1st quarter valued at approximately $38,000. Register Financial Advisors LLC acquired a new stake in shares of Colgate-Palmolive in the 1st quarter valued at approximately $48,000. Finally, Gradient Investments LLC raised its position in shares of Colgate-Palmolive by 150.4% in the 2nd quarter. Gradient Investments LLC now owns 666 shares of the company’s stock valued at $65,000 after acquiring an additional 400 shares during the period. 80.41% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, insider Sally Massey sold 15,850 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the completion of the sale, the insider now owns 13,942 shares of the company’s stock, valued at approximately $1,439,929.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Colgate-Palmolive news, insider Sally Massey sold 15,850 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total transaction of $1,636,988.00. Following the completion of the sale, the insider now owns 13,942 shares of the company’s stock, valued at $1,439,929.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gregory Malcolm sold 10,533 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $103.10, for a total value of $1,085,952.30. Following the sale, the executive vice president now directly owns 10,377 shares of the company’s stock, valued at $1,069,868.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,490 shares of company stock valued at $4,486,063. 0.34% of the stock is owned by insiders.
Colgate-Palmolive Trading Up 0.9 %
Colgate-Palmolive (NYSE:CL – Get Free Report) last released its quarterly earnings data on Friday, July 26th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.87 by $0.04. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $5 billion. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. On average, equities research analysts anticipate that Colgate-Palmolive will post 3.57 EPS for the current fiscal year.
Colgate-Palmolive Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Friday, October 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.00%. The ex-dividend date of this dividend is Friday, October 18th. Colgate-Palmolive’s payout ratio is presently 63.29%.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Bank of America increased their price target on shares of Colgate-Palmolive from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Citigroup increased their target price on Colgate-Palmolive from $103.00 to $112.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Redburn Atlantic raised Colgate-Palmolive to a “hold” rating in a research note on Thursday, August 1st. Finally, Jefferies Financial Group cut Colgate-Palmolive from a “buy” rating to a “hold” rating and lowered their target price for the stock from $103.00 to $95.00 in a research note on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.00.
View Our Latest Analysis on CL
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
See Also
- Five stocks we like better than Colgate-Palmolive
- How to Start Investing in Real Estate
- BlackRock’s Earnings Reveal Market Shift: Why Bonds Are in Favor
- What is the Nikkei 225 index?
- JPMorgan Can Hit New Highs This Year: Here’s Why
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL – Free Report).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.